Fig. 6

High expression of BID associates with sensitivity to SAC abrogation in cancer cell lines of diverse origins (II). A Athymic nude mice bearing NCI-H1819 xenografts were treated with vehicle or AZD2811 nanoparticle formulation (25 mg/kg) once weekly, as indicated by arrows. Tumor volumes were measured by caliper (mean ± SEM, n=9 for each group). Two-way RMANOVA and Bonferroni post-hoc test detected significant differences in Vehicle vs AZD2811 from Day 21 (Day 21,*p<0.05; Days 23 and 25, **p<0.01; Days 28 and 30, ***p<0.001). B Micrographs of SK-MES-1 and NCI-H1819 transfected cells, as explained in (I). AZD2811 was used at 150 nM and doxycycline at 1 µg/mL. C The AURKBi/TTKi-sensitive MDA-MB-468 and NCI-H1819 cells were transfected with shRNA lentiviral particles to silence BID. After puromycin selection, colonies were analyzed by Western blotting. D Dose-response plots to AZD2811 of the colonies selected in (C). E The AURKBi/TTKi-resistant MiaPaCa-2, SK-MES-1 and WM793 cell lines were transfected with the pTRIPZ-BID vector. After puromycin selection, colonies were analyzed by Western blotting. Doxycycline at 1 µg/mL was used to induce ectopic expression of BID. F) Dose-response plots to AZD2811 of the colonies selected in (E)